Clinical Trials in Cleveland

Showing 5461-5480 of 19,775 trials

Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab

NCT06447376

The goal of this clinical trial is to is to determine the safety, feasibility and efficacy of siltuximab prophylaxis of cytokine release syndrome and neurotoxicity occurring after epcoritamab subcutaneous administration for participants with large b-cell lymphoma (DLBCL) or follicular lymphoma (FL). Participants will receive siltuximab, prior to the injection of epcoritamab. Epcoritamab is administered in 28 day cycles for one year. After this injection, the physician will continue to watch participants for side effects and follow the condition for a minimum of 60 days.

Non-Hodgkin LymphomaCytokine Release Syndrome

Taylor Brooks20 participantsStarted Jan 2025

Cleveland, Ohio, United States

COMPLETEDPhase 2< 1 mile

A Study of SEA-CD40 Given With Other Drugs in Cancers

NCT04993677

This trial is being done to see if an experimental drug (SEA-CD40) works when it's given with other cancer drugs to treat some types of cancer. It will also study side effects from the drug. There are 2 parts in this trial. In one part, participants have melanoma that has come back after treatment or can't be removed by surgery. Participants in this part will get SEA-CD40 and pembrolizumab. In the other part, participants have non-small cell lung cancer (NSCLC) that has spread through their body. These participants will get SEA-CD40, pembrolizumab, carboplatin, and pemetrexed.

MelanomaCarcinoma, Non-Small- Cell Lung

Seagen Inc.77 participantsStarted Oct 2021

Springdale, Arkansas, United States • Los Angeles, California, United States • San Francisco, California, United States +26 more locations

Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab

A Study of SEA-CD40 Given With Other Drugs in Cancers

Find Trials by Condition in Cleveland

Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

Phase 2 Study to Assess Efficacy & Safety of WP1302 Prevent Relapse of MMI w/Draw in Subj. w/ Graves' dz

APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML

Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)

Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.

Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC

Sequenced Treatment Effectiveness for Posttraumatic Stress

A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma

A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema

Impairments That Affect Correct Inhaler Use in COPD

Evaluating the Safety and Effectiveness of the InnAVasc Graft for Dialysis Access in Patients With Kidney Failure

Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout

Adalimumab in JIA-associated Uveitis Stopping Trial

M-Vizion™ Macroscopic Radiographic Study

Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC

Trauma Informed Guilt Reduction Therapy

SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma